GlassScriptPhysician profile
Ziad Zaky
NPI 1700057882
$19,654.72
in general payments reported to CMS, 2019-2025
15 companies · $5,209 in 2025
The $5,209 reported for 2025 was more than what 93% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,171 · 2021: $3,223 · 2022: $1,201 · 2023: $3,600 · 2024: $4,252 · 2025: $5,209.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $12K · Food and Beverage: $780 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $12,255.51 |
| Food and Beverage | $780.37 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $6,272.63 | 2023-2025 | |
| Vertex Pharmaceuticals Incorporated | $4,179.74 | 2021-2025 | |
| Apellis Pharmaceuticals, INC. | $3,137.44 | 2025 | |
| Mallinckrodt Enterprises LLC | $2,170.51 | 2019 | |
| Alexion Pharmaceuticals, INC. | $900.00 | 2021-2025 | Ultomiris |
| Zoll Medical Corporation | $711.67 | 2021-2022 | |
| Alnylam Pharmaceuticals INC. | $694.16 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $555.52 | 2024-2025 | Livtencity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $400.00 | 2025 | |
| Aurinia Pharma U.S., INC. | $204.60 | 2023-2024 | Lupkynis |
| Baxter Healthcare | $150.00 | 2023 | Renal - Sharesource |
| Radiometer America, INC | $150.00 | 2025 | |
| Glaxosmithkline, LLC. | $60.00 | 2023 | Benlysta |
| One Lambda, INC. | $43.45 | 2025 | |
| Becton, Dickinson and Company | $25.00 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ziad Zaky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.